EWTX - Company ID 0001710072
The table below shows Edgewise Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$143.82M | -$109.03M | -$91.95M | -$52.63M | -$33.51M | -$14.63M |
| Capital expenditure | $256.00K | $1.31M | $5.75M | $5.55M | $668.00K | $203.00K |
| Investing cash flow | -$32.79M | -$184.66M | $102.89M | -$70.58M | -$242.23M | -$24.38M |
| Dividends paid | - | - | - | - |
Edgewise Therapeutics, Inc. reported operating cash flow of -$143.82M for fiscal year 2025. That is down 31.9% from -$109.03M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$14.63M (FY 2020) to -$143.82M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $196.09M | $249.25M | $53.17M | $129.64M | $186.38M | $120.28M |